Mag7, despite the weaker last session in June (-1.5%), is still the clear leader in H1 2024 with a rate of return of +34.6%. See Figure 1. Small US companies grew only 1.02% during this period. The S&P500 is roughly in the middle with a return of +14.48%.
European companies had a very poor end to the first half of the year (snap elections in France). CAC40 has been down -0.85% since the beginning of the year. Euro Stoxx 50 only +8.24% - see Figure 2.
From the S&P500’s local peak on July 31, 2023 (i.e. for the last 11 months):
Mag7 +44.03%;
S&P500 +18.99%;
Russell 2000 only +2.22%.
See Figure 3. Quarterly rates of return for Mag7 also look interesting (Figure 3, bottom panel): Q3 2023 -2.71%; Q4 2023 +14.46%; Q1 2024 +14.78%, and Q2 2024 +17.27%
Japanese and Chinese stocks have been performing worse recently (Figure 4).
Polish shares provided a similar rate of return to the S&P500 (Figure 5).
H1 2024 is a successful period for companies producing anti-obesity drugs. Eli Lilly (+55.32%) and Novo Nordisk (+37.98%) – Figure 6.
Nividia beats everyone: +149.48% in H1 2024 – see Figure 7.
Detailed summary in Table 1 (there are two versions of the same table with different colors).
